Eric Lefkofsky, Tempus Co-Founder, unlocking the potential of data to fight cancer

The healthcare industry is currently undergoing a race of sorts, a race towards unlocking the potential of healthcare data. Tempus, the data analytical platform co-founded by Eric Lefkofsky, has joined the race in the fight against cancer. Tempus analyzes historical healthcare data from electronic heath records, electronic prescription data, and molecular data from patients, to identify information that can be used to fight cancer in a different way. Technology has enabled healthcare professional to deliver healthcare solutions in a more personalized way. By implementing analytical algorithms to healthcare data, Tempus can create healthcare plans designed to fit the needs of each patient, specific for them.

New Enterprise Associates, Revolution Growth, Kinship Trust Co. and T. Rowe Price Associates are the latest investors, invested $80 million to Tempus. Eric Lefkofsky says the investment are pouring in because of the potential data analytics has on adding value to the lives of cancer patients, and healthcare generally. Tempus has received $210 million in investments since 2015. Tempus is now worth $1.1 billion, making it officially a “unicorn” startup company. Tempus reinvests the funding into human resources, currently employing nearly 400 employees, averaging 30 new workers each month.

Eric graduated from the University of Michigan, and has a Juris Doctor from the University of Michigan Law School. A true serial entrepreneur, Mr. Lefkofsky is also co-founder of groupon the electronic commerce company. Eric Lefkofsky also co-founded on the leading providers of integrated media procurement technology, MediaOcean. Eric is also co-founder of InnerWorking, and Echo Global Logistic. Eric Lefkofsky is also co-founder of UpTake Technologies, another data analytical platform. UpTake is used by companies to analyze data to find ways of improving efficiency and productivity.

The Lefkofsky Family Foundation is a private charitable organization, founded in 2006 by Eric and his wife Liz Lefkofsky. The Lefkofsky Family Foundation was founded to enhance the lives of people in the communities of underserved or neglected areas, delivering opportunities to education, human right protection and expanding cultural initiatives.

Learn More: www.tempus.com/about-us/

Clay Siegall: The Art of Decision Making

 

Every day, we are faced with different choices that we must make. The question is, which one should you pick? A blog post published on Clay Siegall blog state that making the hard decisions will eventually empower you.

Small and hard choices are equally important whether you are making a decision on what to eat for breakfast or choosing between two jobs. Regardless of the situation, you are in; you should proceed with caution because the decision you may make will impact your life in the negative or positive. Fear of the unknown is the motivation behind the decision that you make.

This is just a sneak preview of the wealth of information provided by Clay Siegall and other contributors. You can read more posts on Clay Siegall blog.

About Clay Siegall

Besides being an active blogger with helpful information to share, Clay Siegall is the co-founder of the Seattle Genetics, established in 1998. He is the President and the Chief Executive Officer of the Company. Clay also serves as a member of the Board of Directors of the Company.

Seattle Genetics is a Company that is developing clinical products that will address different types of cancer. Clay has led the Company to achieve significant success. Under his leadership, the Company was able to raise finances through both private and public sources. He has led the Seattle Genetics to partner with other companies including the Genentech for SNG-40.

Before establishing Seattle Genetics, Clay was working with Bristol- Meyers Squibb Pharmaceuticals. He has worked for other Companies before including National Cancer Institute.

Clay also serves as a Board of Directors for several Companies including Alder BioPharmaceuticals, Washington Biotechnology, and Biomedical Association. He is a member of the Board of Governors for Fred Hutchinson Cancer Research Business Alliance.

He holds a Bachelor of Science in Zoology from the University of Maryland and Ph.D. in Genetics from George Washington University.